GPC Biotech Q4 net loss declines to E9.04m
GPC Biotech, a biopharmaceutical company, has reported a net loss of E9.04m, or E0.25 per share, for the fourth quarter of 2008, compared to a net loss of

GPC Biotech, a biopharmaceutical company, has reported a net loss of E9.04m, or E0.25 per share, for the fourth quarter of 2008, compared to a net loss of

Poniard Pharmaceuticals, a biopharmaceutical company, has reached its enrollment target of 400 patients in the Spear trial. This global, pivotal Phase III trial is evaluating the efficacy and

Foley will continue as an employee through December 31, 2009 and will serve as a special advisor to the company during this time and in support of Quidel’s

Discovered by Takeda, Blopress is an angiotensin receptor blocker (ARB) which inhibits action of a vasopressor hormone, angiotensin II. In Japan, it was launched in 1999 and was

John Hunt at the UK Centre for Tissue Engineering at the University of Liverpool and Duncan Graham at the Centre of Molecular NanoMetrology at the University of Strathclyde

The microfluidic cartridge technology was developed specifically to automate the separation of male and female human DNA from forensic samples specifically related to rape cases, the company said.

Adaltis, an in vitro diagnostic company, has reported a net loss of C$14.56m, or C$0.12 per share, for the fourth quarter of 2008, compared to a net loss

According to St Jude Medical, the new fractional flow reserve (FFR) solution, integrated into existing cathlab infrastructure, will enable physicians and cathlab staff immediate access to FFR measurement

The financing was used, in part, to support Aushon’s recent purchase of the SearchLight protein array business and technology assets from Thermo Fisher Scientific. SearchLight assets are currently

Dr Hutson retired from Pfizer in 2006 after spending 25 years in various research and leadership positions with that company, serving most recently as senior vice president of